PD184352 (CI-1040)

Name: PD184352 (CI-1040)
Brand: Selleck Chemicals
SKU: S1020
Rating: 5 (89 reviews)

For research use only.

Catalog No.S1020

89 publications

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. PD184352 (CI-1040) selectively induces apoptosis. Phase 2.

Selleck's PD184352 (CI-1040) has been cited by 89 publications

Cancer Cell, 2020, 37(1):85-103

PubMed: 31935375 ( click the link to review the publication )

Cancer Discov, 2016, 6(8):838-851

PubMed: 27179038 ( click the link to review the publication )

Cancer Cell, 2016, 12;30(3):499-500

PubMed: 27622337 ( click the link to review the publication )

Cancer Cell, 2016, 10.1016/j.ccell.2016.01.006

PubMed: 26859455 ( click the link to review the publication )

Cancer Discov, 2013, 3(9):1058-71

PubMed: 23744832 ( click the link to review the publication )

Cancer Discov, 2012, 2(10):934-47

PubMed: 22961667 ( click the link to review the publication )

Nat Chem Biol, 2012, 8(11):905-912

PubMed: 23023260 ( click the link to review the publication )

Science, 2011, 331(6019):912-6

PubMed: 21330545 ( click the link to review the publication )

Nat Genet, 2011, 44(2):133-9

PubMed: 22197931 ( click the link to review the publication )

Sci Signal, 2020, 28;13(629)

PubMed: 32345725 ( click the link to review the publication )

Cancers (Basel), 2020, 10;12(6):E1516

PubMed: 32531927 ( click the link to review the publication )

Cancers (Basel), 2020, 27;12(5)pii: E1087

PubMed: 32349331 ( click the link to review the publication )

Sci Rep, 2020, 10(1):13124

PubMed: 32753665 ( click the link to review the publication )

Food Funct, 2020, 11(3):2714-2724

PubMed: 32163057 ( click the link to review the publication )

Nat Cell Biol, 2019, 21(6):778-790

PubMed: 31160710 ( click the link to review the publication )

Mol Cell, 2019, 74(5):1086-1102.e5

PubMed: 31101498 ( click the link to review the publication )

Cell Rep, 2019, 28(9):2358-2372

PubMed: 31461652 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):322

PubMed: 31331377 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2019, 32(2):280-291

PubMed: 30277012 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):871

PubMed: 31740667 ( click the link to review the publication )

Sci Rep, 2019, 9(1):13308

PubMed: 31527768 ( click the link to review the publication )

Oncotarget, 2019, 10(56):5755-5767

PubMed: 31645898 ( click the link to review the publication )

EMBO J, 2018, 37(1):19-38

PubMed: 29150432 ( click the link to review the publication )

PLoS Biol, 2018, 16(5):e2003619

PubMed: 29771909 ( click the link to review the publication )
J Cell Biol, 2018, 217(5):1701-1717

PubMed: 29545370 ( click the link to review the publication )

EMBO Rep, 2018, 19(2):320-336

PubMed: 29263201 ( click the link to review the publication )

Elife, 2018, 7

PubMed: 29595474 ( click the link to review the publication )

Elife, 2018, 10.7554/eLife.40167

PubMed: 30561326 ( click the link to review the publication )

Sci Rep, 2018, 8(1):18043

PubMed: 30575780 ( click the link to review the publication )

Nat Chem Biol, 2017, 13(1):38-45

PubMed: 27820799 ( click the link to review the publication )

Cancer Res, 2017, 77(5):1212-1226

PubMed: 28087600 ( click the link to review the publication )

J Hematol Oncol, 2017, 10(1):19

PubMed: 28100259 ( click the link to review the publication )

FASEB J, 2017, 31(5):1903-1915

PubMed: 28174207 ( click the link to review the publication )

Antiviral Res, 2017, 142:178-184

PubMed: 28377100 ( click the link to review the publication )

Biochem Pharmacol, 2017, 136:40-50

PubMed: 28404378 ( click the link to review the publication )

Methods Mol Biol, 2017, 1487:163-174

PubMed: 27924566 ( click the link to review the publication )

J Clin Invest, 2016, 1;126(4):1282-99

PubMed: 26974158 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.11414

PubMed: 26999821 ( click the link to review the publication )

Cell Mol Immunol, 2016, 13(5):658-68

PubMed: 26189368 ( click the link to review the publication )

Oncogene, 2016, 35(29):3854-3865

PubMed: 26657151 ( click the link to review the publication )

Drug Metab Dispos, 2016, 44(5):665-71

PubMed: 26953171 ( click the link to review the publication )

Oncol Lett, 2016, 11(1):99-104

PubMed: 26870175 ( click the link to review the publication )

Eur Rev Med Pharmacol Sci, 2016, 20(10):1961-8

PubMed: 27249593 ( click the link to review the publication )

Oncogene, 2015, 10.1038/onc.2015.12

PubMed: 25684139 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Anim Reprod Sci, 2015, 161:47-57

PubMed: 26307658 ( click the link to review the publication )

J Exp Med, 2015, 212(6):883-92

PubMed: 25987726 ( click the link to review the publication )

Cytometry A, 2015, 10.1002/cyto.a.22628

PubMed: 25598437 ( click the link to review the publication )
eNeuro, 2015, 2(5)

PubMed: 26730399 ( click the link to review the publication )

J Clin Invest, 2014, 124(7):3016-31

PubMed: 24937430 ( click the link to review the publication )

EMBO Mol Med, 2014, 7(1):102-23

PubMed: 25550395 ( click the link to review the publication )

EMBO Mol Med, 2014, 6(6):821-34

PubMed: 24778454 ( click the link to review the publication )

Cancer Lett, 2014, 347(2):212-24

PubMed: 24576622 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):38-49

PubMed: 24650799 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1445

PubMed: 25299770 ( click the link to review the publication )

FASEB J, 2014, 28(10):4551-62

PubMed: 25008089 ( click the link to review the publication )

Mol Cell Proteomics, 2014, 13(6):1429-38

PubMed: 24643969 ( click the link to review the publication )

Biochem J, 2014, 459(3):513-24

PubMed: 24527759 ( click the link to review the publication )

Virology, 2014, 468-470C:490-503

PubMed: 25261871 ( click the link to review the publication )

BMC Cancer, 2014, 14(1):240

PubMed: 24708867 ( click the link to review the publication )

PLoS One, 2014, 9(12):e114389

PubMed: 25486532 ( click the link to review the publication )

Blood, 2013, 121(19):3879-88, S1-8

PubMed: 23460614 ( click the link to review the publication )

J Clin Invest, 2013, 123(11):4786-98

PubMed: 24216509 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6346-58

PubMed: 23966295 ( click the link to review the publication )

Dis Model Mech, 2013, 6(2):521-9

PubMed: 22996645 ( click the link to review the publication )

PLoS One, 2013, 8(10):e76505

PubMed: 24124570 ( click the link to review the publication )

PLoS One, 2013, 8(9):e73548

PubMed: 24019927 ( click the link to review the publication )

PLoS One, 2013, 8(7):e68378

PubMed: 23874604 ( click the link to review the publication )

J Natl Cancer Inst, 2012, 104(21):1673-9

PubMed: 22997239 ( click the link to review the publication )

Oncogene, 2012, 32(38):4480-9

PubMed: 23108403 ( click the link to review the publication )

Breast Cancer Res, 2012, 14(4):R111

PubMed: 22817771 ( click the link to review the publication )
Neoplasia, 2012, 14(4):283-96

PubMed: 22577344 ( click the link to review the publication )

J Biol Chem, 2012, 288(6):4174-93

PubMed: 23255592 ( click the link to review the publication )

J Biol Chem, 2012, 287(33):27863-75

PubMed: 22685289 ( click the link to review the publication )

Mol Endocrinol, 2012, 26(6):1056-73

PubMed: 22570334 ( click the link to review the publication )

Int J Parasitol, 2012, 40(5):555-67

PubMed: 19887070 ( click the link to review the publication )

J Cell Biochem, 2012, 113(1):360-71

PubMed: 21928324 ( click the link to review the publication )

J Biomol Screen, 2012, 17(6):813-21

PubMed: 22453235 ( click the link to review the publication )

J Exp Med, 2011, 208(9):1889-900

PubMed: 21825016 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2011, 108(39):16392-7

PubMed: 21930937 ( click the link to review the publication )

Cell Death Dis, 2011, 2:e124

PubMed: 21368895 ( click the link to review the publication )

Neoplasia, 2011, 13(2):154-66

PubMed: 21403841 ( click the link to review the publication )

Dis Model Mech, 2011, 4(3):393-9

PubMed: 21263000 ( click the link to review the publication )

Antiviral Res, 2011, 92(2):195-203

PubMed: 21854809 ( click the link to review the publication )

Toxicol Sci, 2011, 123(2):542-9

PubMed: 21742783 ( click the link to review the publication )

Front Physiol, 2011, 2:71

PubMed: 22028692 ( click the link to review the publication )

Sci Signal, 2010, 3(149):ra84

PubMed: 21098728 ( click the link to review the publication )

Methods Mol Biol, 2010, 661:107-22

PubMed: 20811979 ( click the link to review the publication )

Purity & Quality Control

Choose Selective MEK Inhibitors

Biological Activity

Description

Features

First MEK inhibitor to begin clinical development.

Targets

MEK1 ^[1] (Cell-free assay)	MEK2 ^[1] (Cell-free assay)
17 nM	17 nM

In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. ^[1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. ^[2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. ^[3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. ^[4]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
H9	MmnmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3niTmlEPTB;MD6wNlI4PiEQvF2=	NXjXc2xLW0GQR1XS
CHP-212	Ml3MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DKSmlEPTB;MD6wNlg5PSEQvF2=	NG\0e\|hUSU6JRWK=
EoL-1-cell	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlXlTWM2OD1yLkC0NVUzKM7:TR?=	MoDHV2FPT0WU
DU-4475	M4XjTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVOzVG1{UUN3ME2wMlA4PTl7IN88US=>	NE\WTndUSU6JRWK=
MMAC-SF	MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LFO2lEPTB;MD6xNFk4PCEQvF2=	M{G3RnNCVkeHUh?=
AGS	NYXZ[3RYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXLWNWF4UUN3ME2wMlEyPzF\|IN88US=>	MV3TRW5ITVJ?
M14	MnLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHJN5FKSzVyPUCuNVU1PjhizszN	NYf0SWg3W0GQR1XS
CP50-MEL-B	NXjHV\|FJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHMTWM2OD1yLkG3NlU1KM7:TR?=	MmHtV2FPT0WU
C32	MmTnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mmf0TWM2OD1yLkG5NFczKM7:TR?=	NEH6NohUSU6JRWK=
KMOE-2	MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYnJR\|UxRTBwMUm3PVUh\|ryP	MX\TRW5ITVJ?
A101D	M3nh[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYXQTWZRUUN3ME2wMlIyPCEQvF2=	M2DjSXNCVkeHUh?=
KM12	M1rTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXvJR\|UxRTBwMkSwOVch\|ryP	M{DucHNCVkeHUh?=
HSC-4	NX7QUno5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWHJR\|UxRTBwMkSzPVUh\|ryP	NVvIeYJxW0GQR1XS
NOMO-1	NEDHcZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVnJR\|UxRTBwMkW3OFIh\|ryP	NYD5TpVkW0GQR1XS
MZ7-mel	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmjxTWM2OD1yLkK2N\|Qh\|ryP	NXPBZZRMW0GQR1XS
ACN	M2LPemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4P0[2lEPTB;MD6yOlc{PyEQvF2=	M2OwTnNCVkeHUh?=
MEL-HO	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4faV2lEPTB;MD6yO\|Y2OiEQvF2=	NIHz[pJUSU6JRWK=
BHT-101	Ml65S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLTbJlVUUN3ME2wMlI5PjB4IN88US=>	MXfTRW5ITVJ?
SK-MEL-28	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{D6TmlEPTB;MD6zNFQxQSEQvF2=	NUTDdYJjW0GQR1XS
KG-1	MlrBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4D5TGlEPTB;MD6zNFY3QCEQvF2=	NHP2bnhUSU6JRWK=
COLO-679	NXm0eGVUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnvHTWM2OD1yLkOyO\|Ih\|ryP	MmK0V2FPT0WU
SK-MEL-24	NXjGc3VXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlroTWM2OD1yLkOyPFE{KM7:TR?=	NELPSGxUSU6JRWK=
G-361	NGDFU3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4qyOGlEPTB;MD6zOlc6PSEQvF2=	MULTRW5ITVJ?
KY821	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{KxUmlEPTB;MD6zO\|kyKM7:TR?=	MYXTRW5ITVJ?
KASUMI-1	NGLqW5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XmbWlEPTB;MD6zPVkh\|ryP	M1TJfnNCVkeHUh?=
HL-60	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFzEVHlKSzVyPUCuOFEyODdizszN	MnfhV2FPT0WU
K5	NX[4Z\|RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwNEOxNVch\|ryP	M4jId3NCVkeHUh?=
KU812	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmrsTWM2OD1yLkS1Nlk6KM7:TR?=	MXvTRW5ITVJ?
SH-4	Mlj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTBwNE[yOVYh\|ryP	NFHWdGhUSU6JRWK=
HTC-C3	NH3LRWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NILhUoVKSzVyPUCuOFY2OzFizszN	NEi3Z3lUSU6JRWK=
CP66-MEL	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljSTWM2OD1yLkS4PFA6KM7:TR?=	NGnVV2VUSU6JRWK=
WM-115	NVLPXJR[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWDJR\|UxRTBwNEmyOVch\|ryP	MnKwV2FPT0WU
A2780	NGjrc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXfJR\|UxRTBwNEm4NlMh\|ryP	MXvTRW5ITVJ?
P12-ICHIKAWA	NFf6N5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTBwNkGyNlEh\|ryP	Mm\xV2FPT0WU
HMV-II	M{O5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmTuTWM2OD1yLk[0OFY2KM7:TR?=	MUTTRW5ITVJ?
HT-144	NHnFdZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3TqbmlEPTB;MD62OFY2PyEQvF2=	NYHnO3N6W0GQR1XS
LB2518-MEL	M3izV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2j5ZmlEPTB;MD63NVY{OiEQvF2=	NH3seldUSU6JRWK=
NCI-SNU-1	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXiTWM2OD1yLke1OFM{KM7:TR?=	NGiyPY1USU6JRWK=
C2BBe1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmnlTWM2OD1yLkixNFI{KM7:TR?=	M2S0SXNCVkeHUh?=
PSN1	NXnKRnhUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTBwOU[xPVYh\|ryP	NXKzWYttW0GQR1XS
UACC-257	NGK2dFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo[3TWM2OD1yLkm2OFc{KM7:TR?=	M{e2fnNCVkeHUh?=
RVH-421	NYXRR2VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\qVoZJUUN3ME2wMlk4OThizszN	NF7pVVhUSU6JRWK=
GP5d	MofUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLoVVRsUUN3ME2wMlk5OzB6IN88US=>	NVj3RYNbW0GQR1XS
TYK-nu	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIjnPZFKSzVyPUGuNFMyPzJizszN	NF;TcHNUSU6JRWK=
SK-N-AS	NWTUPZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnToTWM2OD1zLkC3PVQ4KM7:TR?=	MV\TRW5ITVJ?
SW620	MmLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHTscnRKSzVyPUGuNVM2OzRizszN	MljOV2FPT0WU
HuP-T4	NYTpS\|U5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHH2VYdKSzVyPUGuNVg{PTlizszN	MknoV2FPT0WU
A549	NGDocWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYDJR\|UxRTFwMUm1O\|Yh\|ryP	NVjuOW5zW0GQR1XS
Mewo	NXHBc4RVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3\jeWlEPTB;MT6yNFI4PiEQvF2=	MnXjV2FPT0WU
ONS-76	MniyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFHMcIxKSzVyPUGuNlIxPDlizszN	NH\ido1USU6JRWK=
SK-MEL-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXXJR\|UxRTFwMkO0NVkh\|ryP	NULmT2VmW0GQR1XS
RCM-1	NVvrd\|NjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXPJR\|UxRTFwMkSwOFch\|ryP	NWnjS3h[W0GQR1XS
H-EMC-SS	M2m1Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\ZSGlEPTB;MT6yPVYxQCEQvF2=	NGL2bHFUSU6JRWK=
NCI-H2291	NUfDV4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTFwM{K1N\|Yh\|ryP	NHLueZBUSU6JRWK=
SW1463	MlHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTFwM{O3NlEh\|ryP	NYPxUVd5W0GQR1XS
LS-411N	MlTOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTFwNEC1NVch\|ryP	NF;wNphUSU6JRWK=
BV-173	M{fzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXTJR\|UxRTFwNESwNVUh\|ryP	NVPofI1HW0GQR1XS
LS-513	MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPrZo9KSzVyPUGuOFUyQTJizszN	MkPQV2FPT0WU
LoVo	NXjvUnE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIeyV2tKSzVyPUGuOFY{QTlizszN	NEHVfWFUSU6JRWK=
HO-1-N-1	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3LNR2lEPTB;MT61NVY{PCEQvF2=	NHHnNIpUSU6JRWK=
ML-2	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFT0fVlKSzVyPUGuOVI5PjhizszN	Mn62V2FPT0WU
NCI-H1437	NWW4SGFET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlHLTWM2OD1zLkW1Nlc2KM7:TR?=	MlzZV2FPT0WU
SW1116	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTFwNU[zPVgh\|ryP	MVzTRW5ITVJ?
A4-Fuk	NHrVOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPKUmtKSzVyPUGuOVcxPDVizszN	NWP3fZZbW0GQR1XS
HD-MY-Z	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4G0XmlEPTB;MT61O\|M4PiEQvF2=	NFW0[nFUSU6JRWK=
SK-MEL-2	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MULJR\|UxRTFwNUe0OVkh\|ryP	M{[yOHNCVkeHUh?=
RT-112	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTFwNUi5OVIh\|ryP	NUPQcG1UW0GQR1XS
COLO-829	NXHUZZU{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PIemlEPTB;MT62NlI{OiEQvF2=	NXqwUnhoW0GQR1XS
OVCAR-5	Ml;HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MV;JR\|UxRTFwN{e2PFch\|ryP	NVu5Om5qW0GQR1XS
NB69	NHTzc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmixTWM2OD1zLke4OFY6KM7:TR?=	Mm\qV2FPT0WU
NCI-H292	M13hVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zSZmlEPTB;MT64OlY6QSEQvF2=	MYXTRW5ITVJ?
LOXIMVI	M3v6WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnL4TWM2OD1zLki5OFI4KM7:TR?=	MorhV2FPT0WU
BPH-1	M3fv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3XNZWlEPTB;MT64PVU6OSEQvF2=	Moe4V2FPT0WU
A375	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTFwOEm3NVQh\|ryP	NXjCcWpqW0GQR1XS
LCLC-97TM1	M1\OPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGHITpJKSzVyPUGuPVIzPTZizszN	M3\pPHNCVkeHUh?=
RXF393	NUTh[25MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX;JR\|UxRTFwOUe4PFch\|ryP	NXrudYtVW0GQR1XS
HCC70	NFn5V3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHfx[YJKSzVyPUKuNFI1OjZizszN	MX;TRW5ITVJ?
EM-2	Mn62S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWry[HFnUUN3ME2yMlA4OTl6IN88US=>	NWHQTVB2W0GQR1XS
MZ2-MEL	MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYL2dnRpUUN3ME2yMlEyOTJ5IN88US=>	MXvTRW5ITVJ?
HN	M2TR[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HofmlEPTB;Mj6xOlI4QCEQvF2=	MkjDV2FPT0WU
A2058	NFW1V21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTJwMUmyO\|kh\|ryP	NFOwTVdUSU6JRWK=
NB7	Mm\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHntO5pKSzVyPUKuN\|QxQDZizszN	MYHTRW5ITVJ?
DOK	NHzX[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGGwNlhKSzVyPUKuN\|U4PzNizszN	M{iwRXNCVkeHUh?=
CAL-27	M3m4Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfiT2lKSzVyPUKuN\|kzOzZizszN	MmDvV2FPT0WU
BB65-RCC	NGnQT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3fmV2lEPTB;Mj60NFY4PCEQvF2=	NEjjdHNUSU6JRWK=
RD	NY\jcJE5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXflVlNyUUN3ME2yMlQ1PzJ\|IN88US=>	MoS3V2FPT0WU
KNS-62	NGn0O41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVHJR\|UxRTJwNUGxOlQh\|ryP	M1rEdnNCVkeHUh?=
EW-13	NIq3NFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVX6UYU{UUN3ME2yMlU3OzN7IN88US=>	NIPRNpdUSU6JRWK=
DB	NFjKU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{HJU2lEPTB;Mj61PFc5QCEQvF2=	NYTxXmZoW0GQR1XS
HCC2218	NWLKWFZyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFL6S\|hKSzVyPUKuOlQ4PzhizszN	MnXYV2FPT0WU
L-363	NEPVe4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH:0eFVKSzVyPUKuO\|Q{PyEQvF2=	NXzsN45DW0GQR1XS
CHL-1	M4PCR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M13sdWlEPTB;Mj64NFc5PSEQvF2=	MWTTRW5ITVJ?
BFTC-905	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGG2VnlKSzVyPUKuPFI2OyEQvF2=	M2DQW3NCVkeHUh?=
HCE-T	NVT0SoFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV\JR\|UxRTJwOEOyOlQh\|ryP	M1joV3NCVkeHUh?=
COLO-792	NEf5PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml7xTWM2OD1{Lki0NFI4KM7:TR?=	NWnld4ZEW0GQR1XS
LB2241-RCC	M1;FcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvqeVFKSzVyPUKuPFU5QTNizszN	M3LYWXNCVkeHUh?=
CAL-39	MkLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\pTWM2OD1{Lki5PVk6KM7:TR?=	NGHyU2pUSU6JRWK=
T-24	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUTUS\|BxUUN3ME2yMlkyOTF{IN88US=>	M{O2enNCVkeHUh?=
NCI-H727	NG[wTnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTJwOUG3PVYh\|ryP	MmOyV2FPT0WU
Ca9-22	NUfxc\|QzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn3qTWM2OD1{Lkm3NlU2KM7:TR?=	NE\5SVNUSU6JRWK=
MIA-PaCa-2	Ml6yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHMTWM2OD1\|LkCwO\|gyKM7:TR?=	NVvyZY1pW0GQR1XS
HT-1080	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTNwMEG5PVch\|ryP	M{\1UnNCVkeHUh?=
D-423MG	NWr3eHNUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUTJR\|UxRTNwMEe3OVMh\|ryP	M3;TSHNCVkeHUh?=
LAMA-84	MnXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4m5OGlEPTB;Mz6xN\|U5KM7:TR?=	NHX2bGRUSU6JRWK=
SW780	NXrLPZd{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkHxTWM2OD1\|LkG0NlI6KM7:TR?=	NWO3dldFW0GQR1XS
KU-19-19	NIXaTVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWnJR\|UxRTNwMUewN\|Qh\|ryP	NYXaVGdFW0GQR1XS
COLO-741	NGHxe3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHRU3ZwUUN3ME2zMlE5Pjd\|IN88US=>	NXviXnVNW0GQR1XS
HSC-3	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTNwMkOxOVEh\|ryP	MWXTRW5ITVJ?
SN12C	NFrmdWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vEOWlEPTB;Mz6yOFcxOSEQvF2=	MmDYV2FPT0WU
786-0	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXWVYhKSzVyPUOuNlczPDNizszN	M1K3O3NCVkeHUh?=
GAK	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXGTWM2OD1\|LkOyOVYyKM7:TR?=	NIHJXJJUSU6JRWK=
PANC-03-27	NUTofHVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWLmNXNXUUN3ME2zMlM2ODR3IN88US=>	MoL2V2FPT0WU
CTB-1	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPxepFPUUN3ME2zMlQ4ODR5IN88US=>	NVHkdVhOW0GQR1XS
A427	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2rFdGlEPTB;Mz61PVU2PiEQvF2=	MlTMV2FPT0WU
EGI-1	NFTS[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2rUXWlEPTB;Mz62NFU5OyEQvF2=	M2XrPHNCVkeHUh?=
U-2-OS	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HrfGlEPTB;Mz62O\|I2PiEQvF2=	M37odHNCVkeHUh?=
NCI-SNU-5	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn\vTWM2OD1\|Lk[3O\|Mh\|ryP	MkXUV2FPT0WU
SK-LU-1	M3fv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH3FdIFKSzVyPUOuOlg4QThizszN	M{jMNXNCVkeHUh?=
697	NXPGfm44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{jrfGlEPTB;Mz62PVYxOyEQvF2=	M4XhR3NCVkeHUh?=
HPAF-II	M3zCPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4nyXGlEPTB;Mz63OVQ6KM7:TR?=	MoTwV2FPT0WU
NCI-H2087	Ml3oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmT1TWM2OD1\|Lki0OlczKM7:TR?=	NHqwVY1USU6JRWK=
SK-MEL-3	M1r0Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWLJR\|UxRTNwOEWxOVQh\|ryP	NVfm[HlOW0GQR1XS
CGTH-W-1	NUPkb2xKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTNwOEW3NlUh\|ryP	Mnj5V2FPT0WU
8505C	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYfZO\|E6UUN3ME2zMlkxODd6IN88US=>	NYDUPIs{W0GQR1XS
GAMG	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mly2TWM2OD12LkCyN\|c4KM7:TR?=	Mn\3V2FPT0WU
SW626	M3i1R2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLOTWM2OD12LkC0OFgh\|ryP	NHfFZ4pUSU6JRWK=
CAL-62	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkX4TWM2OD12LkC3OFMh\|ryP	NYT2RWdPW0GQR1XS
MHH-PREB-1	NX;ycIhRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUnnW3J6UUN3ME20MlEzOTFzIN88US=>	NUniZVg{W0GQR1XS
RPMI-7951	M2PHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWrLS49uUUN3ME20MlI2PTh7IN88US=>	Ml[yV2FPT0WU
HOP-92	Mm\PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NG\aN3JKSzVyPUSuNlU3PyEQvF2=	MmLoV2FPT0WU
MDA-MB-231	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXX1SWp3UUN3ME20MlI6OjJ\|IN88US=>	NEXUdnZUSU6JRWK=
LAN-6	Mn\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XjXWlEPTB;ND6zNVY{PyEQvF2=	MonDV2FPT0WU
ALL-PO	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnHsTWM2OD12LkO2NVU3KM7:TR?=	MmS4V2FPT0WU
HH	NIXhOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnmbmZKSzVyPUSuOFE2QTdizszN	NE\vflNUSU6JRWK=
IGROV-1	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDOfW1bUUN3ME20MlQ2OTdzIN88US=>	M4T1enNCVkeHUh?=
NCI-H358	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLITWM2OD12LkS1N\|g2KM7:TR?=	MYfTRW5ITVJ?
NB5	MofTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{G5RWlEPTB;ND62NFM3QSEQvF2=	M1LHPHNCVkeHUh?=
NCI-H747	NYjuRYd2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVHEWIdtUUN3ME20MlY5QDB5IN88US=>	NHPhVZpUSU6JRWK=
NH-12	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkToTWM2OD12LkexOlI2KM7:TR?=	NHjaTnVUSU6JRWK=
LB1047-RCC	M4KzbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1z2bGlEPTB;ND63N\|gyPSEQvF2=	NID5XmVUSU6JRWK=
EFO-27	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLrO41KSzVyPUSuO\|g3PjdizszN	M{G2R3NCVkeHUh?=
EPLC-272H	M1HrO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXPYdWx{UUN3ME20Mlk6PjZ7IN88US=>	MWrTRW5ITVJ?
CAL-54	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVjJR\|UxRTVwMEK2PVUh\|ryP	MXHTRW5ITVJ?
H4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TRdGlEPTB;NT6wOFI2PSEQvF2=	NIrNXJNUSU6JRWK=
MOLT-13	NYPoUnJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYC1cFd{UUN3ME21MlA3Pzd4IN88US=>	NEiw[HVUSU6JRWK=
CAL-33	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3nwcmlEPTB;NT6xNlMyPyEQvF2=	Mn\VV2FPT0WU
23132-87	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTVwMU[4O\|Ih\|ryP	M{TnVHNCVkeHUh?=
UM-UC-3	M33sdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoPtTWM2OD13LkG4NFQ4KM7:TR?=	MnLlV2FPT0WU
HuH-7	NV7wNGtRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYLJR\|UxRTVwMkexOFch\|ryP	NVL6bJdTW0GQR1XS
BCPAP	NX3zOHhJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlnlTWM2OD13LkOyPVY6KM7:TR?=	NFTyfXNUSU6JRWK=
AsPC-1	NHzaNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTVwM{[3OlMh\|ryP	NE\RUo9USU6JRWK=
NCI-H1155	M1TPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3viTGlEPTB;NT60NFA2OSEQvF2=	NXi5VoNsW0GQR1XS
GT3TKB	NYLNS2pST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVrJR\|UxRTVwNE[1PVgh\|ryP	NWjrW5VSW0GQR1XS
HCC2998	M13OT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoLyTWM2OD13LkS5NVA6KM7:TR?=	NGfqW5BUSU6JRWK=
NUGC-3	MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TCPWlEPTB;NT60PVMxOiEQvF2=	NHG5b\|hUSU6JRWK=
Hs-578-T	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkL4TWM2OD13LkWzO\|k1KM7:TR?=	MXnTRW5ITVJ?
FADU	Mom3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fTcGlEPTB;NT61OVczPiEQvF2=	MmTpV2FPT0WU
NBsusSR	M17Ib2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlvPTWM2OD13LkW3NVU2KM7:TR?=	MWnTRW5ITVJ?
ME-180	M{X1Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{mzeGlEPTB;NT61PFA6OiEQvF2=	NV3hdplmW0GQR1XS
SW1710	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTVwNkG2OVQh\|ryP	NGHteoRUSU6JRWK=
HuP-T3	M3f6Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1H1O2lEPTB;NT62NlAzQSEQvF2=	NGD1PVFUSU6JRWK=
HOS	NFvzN2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\uTWM2OD13Lk[yPVI{KM7:TR?=	M2XZfXNCVkeHUh?=
PA-1	NF24[ZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1PMeWlEPTB;NT62OFI3PSEQvF2=	MVfTRW5ITVJ?
LU-99A	NGeybXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkHsTWM2OD13Lk[2OFUyKM7:TR?=	M3\2bnNCVkeHUh?=
RS4-11	Ml;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkfXTWM2OD13Lk[2O\|c2KM7:TR?=	NXnrfppQW0GQR1XS
TE-8	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDnR4JqUUN3ME21MlY5PTN5IN88US=>	MmXjV2FPT0WU
RERF-LC-MS	M1HTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFy5VZBKSzVyPUWuOlg5ODNizszN	MoPRV2FPT0WU
MEL-JUSO	NHu4VYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVTJR\|UxRTVwN{O3PEDPxE1?	NUTuNlNpW0GQR1XS
SK-MES-1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnm5TWM2OD13LkizOVI5KM7:TR?=	NYjLRWFIW0GQR1XS
D-263MG	Mm\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3LlTmlEPTB;NT64PFM2OSEQvF2=	MXLTRW5ITVJ?
NB10	M3jvcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3QXGVKSzVyPUWuPFk1PiEQvF2=	M{\4PHNCVkeHUh?=
SK-HEP-1	NUWySYNLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoXNTWM2OD13LkmzOFcyKM7:TR?=	M1LLPHNCVkeHUh?=
HT-29	Mni1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXuR5ZFUUN3ME21Mlk5OTF6IN88US=>	MmTxV2FPT0WU
KYSE-140	NWewdWxuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M33KbWlEPTB;Nj6wNlE5OiEQvF2=	NXjQfYg4W0GQR1XS
NCI-H1666	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWfaWIdDUUN3ME22MlA5PDZzIN88US=>	MVPTRW5ITVJ?
NCI-H1304	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M13TcGlEPTB;Nj6xPVk1KM7:TR?=	NXjOclFTW0GQR1XS
RPMI-8866	M4HwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHGb2F3UUN3ME22MlIyOzF\|IN88US=>	Ml:5V2FPT0WU
MV-4-11	M4S2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHtXmFKSzVyPU[uNlMyQTlizszN	NVXDRWQzW0GQR1XS
A431	MnfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfZTWM2OD14LkK0Nlk3KM7:TR?=	Mor3V2FPT0WU
PANC-10-05	NYPkUlZ2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\BXGlEPTB;Nj6yPFM3OyEQvF2=	MVvTRW5ITVJ?
TK10	M1v6d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnO1TWM2OD14LkOyOlA1KM7:TR?=	NWezTIx6W0GQR1XS
NCI-H1975	NGLCTm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGPicY9KSzVyPU[uOFczOTVizszN	Mn7WV2FPT0WU
A172	NX[yPY9ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoHSTWM2OD14LkS5NVc3KM7:TR?=	MliwV2FPT0WU
D-566MG	NIP1VJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mlu2TWM2OD14LkW0N\|A{KM7:TR?=	MnW1V2FPT0WU
NCI-H2122	NGiySFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLkTWM2OD14Lk[xOVI5KM7:TR?=	MlfYV2FPT0WU
COR-L105	NIr3[VdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHCTWM2OD14Lk[1Nlc2KM7:TR?=	Mn\tV2FPT0WU
AN3-CA	M4PRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYLJR\|UxRTZwNki2OFEh\|ryP	NHPpbINUSU6JRWK=
Calu-6	NF3XTGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1HoNWlEPTB;Nj63PVY6QCEQvF2=	MVjTRW5ITVJ?
HCT-116	NFLhUIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE[2[2pKSzVyPU[uPFEzPjRizszN	NIPqcmdUSU6JRWK=
MHH-NB-11	NWjROYNNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTZwOEWwNFIh\|ryP	NE\OVnNUSU6JRWK=
MFE-280	NIS3V3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{DSNWlEPTB;Nj64OVk5OyEQvF2=	NUizVINVW0GQR1XS
SW1088	NFjqdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\QTWM2OD14LkmxPVE{KM7:TR?=	NHXo[mxUSU6JRWK=
SW48	M1TlN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfPVYlGUUN3ME22Mlk1PTFizszN	NWHZeVNHW0GQR1XS
HuCCT1	MlexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHfjeZFKSzVyPUeuNFExOzdizszN	NF3QZlJUSU6JRWK=
ACHN	MknPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmDMTWM2OD15LkCyPVQ{KM7:TR?=	NWS5ZnR[W0GQR1XS
8305C	NVrJXnBIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorVTWM2OD15LkC5PVk2KM7:TR?=	NUfBR4VwW0GQR1XS
DoTc2-4510	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrw[XYyUUN3ME23MlEzOTVizszN	Mn;OV2FPT0WU
COR-L23	NXXBbI1OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37sU2lEPTB;Nz6yOFQzKM7:TR?=	Mkj3V2FPT0WU
SK-MEL-30	M{jvfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHW4UWVKSzVyPUeuNlUxQDNizszN	M{TrVHNCVkeHUh?=
BE-13	NWqyfYE2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHOTWM2OD15LkOzPFM1KM7:TR?=	NXfGOoM2W0GQR1XS
GR-ST	MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NY\xeIZlUUN3ME23MlQxOTd2IN88US=>	MnLEV2FPT0WU
LU-135	M1[3TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTdwNUW5N\|kh\|ryP	MWHTRW5ITVJ?
U-266	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PEbmlEPTB;Nz61OlI5PiEQvF2=	NFjwcYtUSU6JRWK=
NCI-H1355	M4Xkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2m2T2lEPTB;Nz61PFY{PSEQvF2=	MlXMV2FPT0WU
NB14	MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnviTWM2OD15Lk[2OlQzKM7:TR?=	M{PueXNCVkeHUh?=
SCC-25	NVrZVmNFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1XsbGlEPTB;Nz63NFkh\|ryP	MWnTRW5ITVJ?
COLO-678	NG\YUo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX24TmV7UUN3ME23MlcyODd4IN88US=>	NVG5RZNnW0GQR1XS
TGBC1TKB	Mnm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWHJR\|UxRTdwOEmzPVgh\|ryP	MkTBV2FPT0WU
IST-MEL1	NGPtVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\jfWlEPTB;OD6wNFQxPiEQvF2=	NGLVT5RUSU6JRWK=
ECC10	MojnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH\nSWVKSzVyPUiuNFM{QTVizszN	MoD1V2FPT0WU
EW-16	NVHhblJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXvJR\|UxRThwMEi0OFUh\|ryP	Ml\HV2FPT0WU
DOHH-2	M3\DTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{f4bGlEPTB;OD6yNFA6PSEQvF2=	NHzuO49USU6JRWK=
NCI-H1581	NF;GeW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1\NUGlEPTB;OD6yOlMzOyEQvF2=	MlP2V2FPT0WU
TE-5	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX7zS3Z1UUN3ME24MlQzPDJ7IN88US=>	NFnoZnVUSU6JRWK=
CAKI-1	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHG5c3FKSzVyPUiuOVczOjJizszN	MVrTRW5ITVJ?
A673	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF:xVoNKSzVyPUiuOlMzODJizszN	M{G5ZXNCVkeHUh?=
CAL-12T	NFX3cFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1iydmlEPTB;OD62OVc2OyEQvF2=	MmLNV2FPT0WU
DBTRG-05MG	NFrSZ5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRThwN{S4OVkh\|ryP	M{HsTXNCVkeHUh?=
SK-N-FI	NHvCTYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUmzW5FvUUN3ME24MlgyOzd7IN88US=>	MVrTRW5ITVJ?
K-562	M2PVVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIjwVZZKSzVyPUiuPFM6PTdizszN	M16weHNCVkeHUh?=
SBC-1	NH:0R41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2m2ZmlEPTB;OD64OlY1PSEQvF2=	NUXNRpJ2W0GQR1XS
ES4	NF[4e4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnRW\|dmUUN3ME24Mlg3QDh2IN88US=>	NIfwTolUSU6JRWK=
MS-1	NHrD[4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFzMSFhKSzVyPUiuPFc2OTdizszN	M1vOXXNCVkeHUh?=
RKO	Mk\rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1nIdWlEPTB;OD64PVA2PyEQvF2=	M3H0cXNCVkeHUh?=
NCI-H1693	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NICxNI1KSzVyPUiuPVIyPyEQvF2=	MmD2V2FPT0WU
SW954	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLyTWM2OD16Lkm2PVc5KM7:TR?=	Ml;OV2FPT0WU
SK-UT-1	NHfi[GZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLHTWM2OD16Lkm3Olg{KM7:TR?=	NVW5dHZ3W0GQR1XS
T98G	NV;5NFlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF\hTJRKSzVyPUiuPVk5PDZizszN	MW\TRW5ITVJ?
NCI-H2126	NFvVfo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWDPVGxiUUN3ME25MlAxQDJ4IN88US=>	M1HUZXNCVkeHUh?=
TE-12	NXvoWZpOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFXYbWlKSzVyPUmuNFM{PjdizszN	M4XJb3NCVkeHUh?=
DK-MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTlwMkGxPVEh\|ryP	NIDY[41USU6JRWK=
MEG-01	MmjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{H3UWlEPTB;OT6yOFk{OSEQvF2=	NYexZWVYW0GQR1XS
HCC1937	M13DXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;IcHBHUUN3ME25MlI6ODlzIN88US=>	MkPWV2FPT0WU
MKN45	NVP6WXFOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUfJR\|UxRTlwNEWwOlUh\|ryP	NHrKVndUSU6JRWK=
NCI-H1792	Mm\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHznTWRKSzVyPUmuOFUzOTlizszN	NXfIb4NCW0GQR1XS
SW1417	NF[xWFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIr0XmVKSzVyPUmuOVY5OzdizszN	NYLR[ndkW0GQR1XS
639-V	M1nrOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M33SfmlEPTB;OT62OFM5QCEQvF2=	MoqyV2FPT0WU
P30-OHK	MlnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUf1U2RSUUN3ME25MlY2OzF4IN88US=>	MXjTRW5ITVJ?
YKG-1	M3jscGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTlwN{WwN\|Mh\|ryP	Mk\PV2FPT0WU
KGN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUjJR\|UxRTlwOEO3PVUh\|ryP	MmTjV2FPT0WU
MSTO-211H	MlvsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXzJR\|UxRTlwOUW1Nlkh\|ryP	NV3ufVhSW0GQR1XS
NCI-H1573	NHnn[o5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTFyLkG1O\|Qh\|ryP	NI\1WFlUSU6JRWK=
NCI-H720	Mn;PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU\a[49LUUN3ME2xNE4yQTh7IN88US=>	MoHPV2FPT0WU
KARPAS-45	NHXWTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mmr4TWM2OD1zMD6yO\|k2KM7:TR?=	NVr2UYl6W0GQR1XS
MDA-MB-175-VII	NUnnUWs4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3jZSWlEPTB;MUCuOFgh\|ryP	NF:1SXBUSU6JRWK=
SK-NEP-1	M{\KcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlPGTWM2OD1zMD60PVgyKM7:TR?=	MYHTRW5ITVJ?
MKN28	M3f2T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfaTWM2OD1zMD61NVgh\|ryP	MV3TRW5ITVJ?
KYSE-520	NGnz[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjOV3lFUUN3ME2xNE42OiEQvF2=	MWfTRW5ITVJ?
KE-37	M2\Dcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{PCW2lEPTB;MUCuOVI4OiEQvF2=	M3;yNHNCVkeHUh?=
VA-ES-BJ	NUPYTXZbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX6zfopDUUN3ME2xNE42PjdizszN	M4TmZXNCVkeHUh?=
CCRF-CEM	NEnubVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVPofXY6UUN3ME2xNE42Pjh2IN88US=>	NXTGXW5tW0GQR1XS
GMS-10	NGLKc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVvob5ZpUUN3ME2xNE43ODl2IN88US=>	M1LGUnNCVkeHUh?=
NCI-H1623	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWXJR\|UxRTFyLk[zO\|kh\|ryP	NXTyVlBpW0GQR1XS
NEC8	NIfIXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlKzTWM2OD1zMD63O\|c{KM7:TR?=	M3PXXXNCVkeHUh?=
MOLT-16	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoPDTWM2OD1zMD64NVE{KM7:TR?=	MYfTRW5ITVJ?
DJM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmfVTWM2OD1zMT6wN\|c6KM7:TR?=	M1njcHNCVkeHUh?=
U251	NF24ellIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlKwTWM2OD1zMT6wOFIh\|ryP	Ml;IV2FPT0WU
SBC-5	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnoTGtQUUN3ME2xNU4yPDZ5IN88US=>	MXPTRW5ITVJ?
SW756	NXfZPGtUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\CTWM2OD1zMT6yNVU1KM7:TR?=	MWTTRW5ITVJ?
KS-1	NVPxNVJST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV7JR\|UxRTFzLkK2NVkh\|ryP	M1\WS3NCVkeHUh?=
SF295	NWHR[GpYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkmyTWM2OD1zMT6zNVA1KM7:TR?=	NVjnc29yW0GQR1XS
YH-13	NWXhWol{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4HuVGlEPTB;MUGuN\|I3PyEQvF2=	Mn;IV2FPT0WU
SW837	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TiV2lEPTB;MUGuN\|UxPiEQvF2=	NEXtdZNUSU6JRWK=
KYSE-450	NVHCSoRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWSxNpQ3UUN3ME2xNU41ODV5IN88US=>	NYSzbWNJW0GQR1XS
KYSE-180	NIHKdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWLGT4F4UUN3ME2xNU41QDJizszN	M1W5U3NCVkeHUh?=
S-117	NIXkcpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX3JR\|UxRTFzLkS4PVYh\|ryP	MXrTRW5ITVJ?
KOSC-2	NH7zWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3P3TGlEPTB;MUGuOlIzOiEQvF2=	M{Pu[HNCVkeHUh?=
KYSE-270	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWTJR\|UxRTFzLki3OFUh\|ryP	NFT0PYlUSU6JRWK=
D-336MG	M{j6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\ZRmlEPTB;MUGuPVA4PSEQvF2=	NVnUO\|RxW0GQR1XS
KALS-1	NV\scXMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlvlTWM2OD1zMj6wNFE3KM7:TR?=	NE[4UmhUSU6JRWK=
LB373-MEL-D	M3W1Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1;rcmlEPTB;MUKuNFU{OyEQvF2=	NHj6UmdUSU6JRWK=
HLE	Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MU\JR\|UxRTF{LkC1PFUh\|ryP	Mnm1V2FPT0WU
SJSA-1	NWHqXIdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV3oZYZ7UUN3ME2xNk4xPzN3IN88US=>	MoLiV2FPT0WU
SW1990	NYjQT4dMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYjJR\|UxRTF{LkC5NVEh\|ryP	M3S2SHNCVkeHUh?=
NOS-1	M3jINmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkH1TWM2OD1zMj6xN\|UzKM7:TR?=	NXfRPXhLW0GQR1XS
GI-ME-N	NXy1fZA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIrjVZlKSzVyPUGyMlIyPjNizszN	NEPJNVNUSU6JRWK=
NCI-H1703	NVnYNVQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWHPVno5UUN3ME2xNk4zPjF4IN88US=>	MmC1V2FPT0WU
ES7	Mk[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{j6SGlEPTB;MUKuNlczPCEQvF2=	MUTTRW5ITVJ?
KYSE-510	M1ywUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWfCfol{UUN3ME2xNk42ODd7IN88US=>	NGD0UlhUSU6JRWK=
BHY	NEPJcJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfJTWM2OD1zMj61N\|A4KM7:TR?=	MnL0V2FPT0WU
TCCSUP	NY\ic\|l[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnrkTWM2OD1zMj61O\|U4KM7:TR?=	MWLTRW5ITVJ?
HSC-2	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXHJR\|UxRTF{LkW5PVYh\|ryP	M4XyW3NCVkeHUh?=
BEN	NEL1cY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIXDRoVKSzVyPUGyMlYyPDNizszN	NI\xR\|VUSU6JRWK=
769-P	NIPKSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUP0bolUUUN3ME2xNk44QTJ2IN88US=>	MYLTRW5ITVJ?
HT	NIfRT4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVjWUIVLUUN3ME2xNk45OzR4IN88US=>	NX;ESXlHW0GQR1XS
LXF-289	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkDSTWM2OD1zMj65OVMyKM7:TR?=	M1zFS3NCVkeHUh?=
OVCAR-3	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEfBXm1KSzVyPUGyMlk2PjdizszN	NUT0[Vc4W0GQR1XS
ATN-1	MnP0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXPFUGJ4UUN3ME2xN{4xOTh2IN88US=>	MXfTRW5ITVJ?
8-MG-BA	NXXyfIVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2fKNWlEPTB;MUOuNFQ2PSEQvF2=	MlS0V2FPT0WU
SW13	NYHHOlI5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIHqZWhKSzVyPUGzMlEyPjVizszN	MnfyV2FPT0WU
NCI-H1092	NIrMS\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[5fIRKSzVyPUGzMlE3OiEQvF2=	MV;TRW5ITVJ?
OAW-42	NVTPRmg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7nfFhWUUN3ME2xN{4yQTN5IN88US=>	MX\TRW5ITVJ?
NCI-H2452	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDlOGRyUUN3ME2xN{4zOTd3IN88US=>	MXrTRW5ITVJ?
CAPAN-1	NH62XHBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTF\|LkW1NVQh\|ryP	MXTTRW5ITVJ?
NCI-H2009	NXLBT2JLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWnKZlNTUUN3ME2xN{42QTF7IN88US=>	MmjWV2FPT0WU
SF268	MlvnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MkHYTWM2OD1zMz62N\|I3KM7:TR?=	NEnFTJpUSU6JRWK=
GCIY	NUTQVlVMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HXRmlEPTB;MUOuOlkzPyEQvF2=	MnX0V2FPT0WU
OS-RC-2	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1q5UGlEPTB;MUOuPVUxOSEQvF2=	MonLV2FPT0WU
GCT	M4rmb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NGDaVYFKSzVyPUGzMlk3QTdizszN	NGe1T2JUSU6JRWK=
NB17	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFHue\|NKSzVyPUG0MlA5PSEQvF2=	MoDFV2FPT0WU
NCI-H2030	NH7sSFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HlSGlEPTB;MUSuNVQ3PSEQvF2=	M37XW3NCVkeHUh?=
HC-1	NHLYT4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXoUGtKSzVyPUG0MlIxQDdizszN	MVrTRW5ITVJ?
QIMR-WIL	NID3S5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlnWTWM2OD1zND6zOFEzKM7:TR?=	MmHoV2FPT0WU
Capan-2	Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVW2TZlFUUN3ME2xOE4{PzF2IN88US=>	M{PxOXNCVkeHUh?=
BALL-1	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFe3S4lKSzVyPUG0MlQ3PjVizszN	MlXvV2FPT0WU
LS-1034	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUPJR\|UxRTF2Lk[xOVIh\|ryP	NYnVTHZsW0GQR1XS
U-118-MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3f5[WlEPTB;MUSuOlMyKM7:TR?=	NWHuelBRW0GQR1XS
NCI-H630	NUnuc5JrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1jFN2lEPTB;MUSuOlU3QCEQvF2=	NVTkOZltW0GQR1XS
OVCAR-8	NHLMRmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUHlVoJSUUN3ME2xOE44OjBzIN88US=>	MYPTRW5ITVJ?
NCI-H2347	NFXyR\|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[2T5hKSzVyPUG0MlgzOyEQvF2=	MkjhV2FPT0WU
BT-549	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NETr[5ZKSzVyPUG0MlgzQDRizszN	NHjlbWFUSU6JRWK=
LB831-BLC	NFW3NpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTF2Lki5N\|Qh\|ryP	NE[2bHZUSU6JRWK=
NCI-H661	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MknBTWM2OD1zND65OVkh\|ryP	NETydpRUSU6JRWK=
MKN7	MlXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHXuR2lKSzVyPUG1MlAxQTNizszN	NVjscnloW0GQR1XS
U-87-MG	M1LiUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF3rbFhKSzVyPUG1MlA5QTdizszN	M162SXNCVkeHUh?=
OVCAR-4	M1\Fe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmmxTWM2OD1zNT6xOFI1KM7:TR?=	MX\TRW5ITVJ?
OE33	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXHYPVNCUUN3ME2xOU4yPzFzIN88US=>	MVLTRW5ITVJ?
EC-GI-10	MoLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH3INldKSzVyPUG1MlI{PTdizszN	M33uZ3NCVkeHUh?=
AM-38	M3zrbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4n4Z2lEPTB;MUWuNlcyPyEQvF2=	Mn3sV2FPT0WU
NCI-H1563	MmHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEPrXVJKSzVyPUG1MlM1QSEQvF2=	M3mzTXNCVkeHUh?=
SCC-4	NVfuV3RMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXDbpFKSzVyPUG1MlQyODNizszN	M{PmZXNCVkeHUh?=
Detroit562	M1S0PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHvoV5pKSzVyPUG1MlQ2PDdizszN	MWnTRW5ITVJ?
PC-14	NXzrNVFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXTJR\|UxRTF3LkS4OlYh\|ryP	M{nxc3NCVkeHUh?=
ES3	MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHG2NphKSzVyPUG1MlU{PiEQvF2=	NEPBPFFUSU6JRWK=
OCI-AML2	MnTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnn3TWM2OD1zNT63OlE1KM7:TR?=	NG\OPZJUSU6JRWK=
LU-134-A	M4nkTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1PDVGlEPTB;MUWuPVAyQCEQvF2=	M3L0OnNCVkeHUh?=
SAS	NFT6UphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWXJR\|UxRTF3LkmzO\|Mh\|ryP	MYfTRW5ITVJ?
TGBC11TKB	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mnu0TWM2OD1zNT65OFE1KM7:TR?=	NUTpNHZUW0GQR1XS
HOP-62	NUn6[3F{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnmxTWM2OD1zNT65OVk4KM7:TR?=	NFzlTINUSU6JRWK=
G-401	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn7vTWM2OD1zNT65OlQ6KM7:TR?=	MYPTRW5ITVJ?
NCI-H28	M3faS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTF4LkC4OVYh\|ryP	MVLTRW5ITVJ?
A204	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGLQVIdKSzVyPUG2MlIxODZizszN	M1LuTHNCVkeHUh?=
NCI-H1299	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrOXZpKSzVyPUG2MlIzQTFizszN	MYPTRW5ITVJ?
VMRC-RCZ	M1mwR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3K1c2lEPTB;MU[uNlU6OiEQvF2=	NUPrXHNYW0GQR1XS
BxPC-3	NXTzdGM1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DuWmlEPTB;MU[uNlg2PiEQvF2=	NXe2SFlqW0GQR1XS
NCI-H2228	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2DqT2lEPTB;MU[uOVE2QCEQvF2=	MkDoV2FPT0WU
NCI-H23	M{\0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHfM[mtKSzVyPUG2MlYxPzhizszN	NFHC[pRUSU6JRWK=
NKM-1	M2KxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTF5LkCxPFkh\|ryP	MYjTRW5ITVJ?
KYSE-70	M133XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1fUeWlEPTB;MUeuNlg6KM7:TR?=	M4T5PXNCVkeHUh?=
BB49-HNC	NXy0Xm83T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\BTWM2OD1zNz61Olg3KM7:TR?=	NUDTTW9iW0GQR1XS
SCC-15	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1XwbWlEPTB;MUeuPFQ4OyEQvF2=	M1i1b3NCVkeHUh?=
D-247MG	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M33OdmlEPTB;MUeuPVI1PyEQvF2=	M{i3NnNCVkeHUh?=
BB30-HNC	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnX5TWM2OD1zOD6wN\|E5KM7:TR?=	NWD5bppWW0GQR1XS
CAL-85-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MluxTWM2OD1zOD6xPFA6KM7:TR?=	NWnWbXo6W0GQR1XS
HT-3	MkTjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnOzTWM2OD1zOD6zPVc4KM7:TR?=	MWHTRW5ITVJ?
KYSE-410	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\ITWM2OD1zOD60OVc4KM7:TR?=	MXXTRW5ITVJ?
SW982	MnXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVvJR\|UxRTF6LkW2OFkh\|ryP	NXLuXI93W0GQR1XS
SW962	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFToeYhKSzVyPUG4MlU4ODJizszN	MYXTRW5ITVJ?
Ramos-2G6-4C10	NEnHd3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTMOZdbUUN3ME2xPE42QTJ5IN88US=>	MX3TRW5ITVJ?
OC-314	NV\0fHdJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYXLOWNkUUN3ME2xPE44Ozh2IN88US=>	NIXjW5FUSU6JRWK=
LS-123	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4\LdWlEPTB;MUiuO\|kxOSEQvF2=	NVTyW4l2W0GQR1XS
D-502MG	M3XVc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoDzTWM2OD1zOD64NVM6KM7:TR?=	M2nKTXNCVkeHUh?=
RO82-W-1	MnX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HwSGlEPTB;MUiuPFI5QCEQvF2=	MV3TRW5ITVJ?
HuO9	NUDqZYVXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHrOOnRKSzVyPUG5MlE{PzlizszN	NFH6flJUSU6JRWK=
ETK-1	MmDFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXHJR\|UxRTF7LkG4Nlch\|ryP	NIfyTZdUSU6JRWK=
SNU-387	MmXFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoDCTWM2OD1zOT6xPFg6KM7:TR?=	Moj3V2FPT0WU
SW1573	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M331XmlEPTB;MUmuNVk3QSEQvF2=	M3nJfnNCVkeHUh?=
NTERA-S-cl-D1	M3fy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTF7LkKwNFch\|ryP	NIPMO2ZUSU6JRWK=
SF126	M4noV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVjMRlBDUUN3ME2xPU4{PTB{IN88US=>	NEjH[opUSU6JRWK=
Calu-3	NHPoSYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:zTWM2OD1zOT60NlM4KM7:TR?=	M1HpSXNCVkeHUh?=
NCI-H1048	M3jJfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\XTWM2OD1{MD6zNlY3KM7:TR?=	M3vrSXNCVkeHUh?=
NCI-H226	NWO4ZnFIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1fpd2lEPTB;MkCuOFM6QSEQvF2=	NIfXVIlUSU6JRWK=
FTC-133	NETNTpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M17NcGlEPTB;MkCuOFcxOyEQvF2=	MXvTRW5ITVJ?
SF539	NYXSNnNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3HWTGlEPTB;MkCuOVE4OiEQvF2=	NV\5[mRWW0GQR1XS
TE-6	NV[1dVJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3L3VWlEPTB;MkCuPFA3PyEQvF2=	Mn;4V2FPT0WU
UMC-11	MkOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTJyLkmxOlQh\|ryP	M4O4bXNCVkeHUh?=
Becker	NF[yZ5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofMTWM2OD1{MT6xNVE5KM7:TR?=	NFS4UHhUSU6JRWK=
KP-4	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYPiU2FOUUN3ME2yNU4yOTl4IN88US=>	MX;TRW5ITVJ?
ChaGo-K-1	NYPYdpF5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\CTWM2OD1{MT6zOlI4KM7:TR?=	M3zudHNCVkeHUh?=
CFPAC-1	MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVXJR\|UxRTJzLkO4OVgh\|ryP	MkO2V2FPT0WU
A498	M1zBTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYrGTG9nUUN3ME2yNU42OzF{IN88US=>	NWXJdYplW0GQR1XS
NCI-H1755	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnkfYtKSzVyPUKxMlY4PDFizszN	M1Hqb3NCVkeHUh?=
TI-73	NH7VbG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLOTWM2OD1{Mj6zNlgh\|ryP	MWXTRW5ITVJ?
NCI-H441	M1fmeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlfFTWM2OD1{Mj61Olg6KM7:TR?=	MVHTRW5ITVJ?
CaR-1	MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mne2TWM2OD1{Mz6wNlE{KM7:TR?=	NXTY[4NoW0GQR1XS
HCC1806	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPpTWM2OD1{Mz6wOVg{KM7:TR?=	Ml7UV2FPT0WU
SNU-449	NILWbWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTJ\|LkOyPUDPxE1?	MmjPV2FPT0WU
EKVX	NWnTR3F4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTJ\|LkO5NFkh\|ryP	NX;uPWpzW0GQR1XS
DMS-114	MlXWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[5TWM2OD1{Mz61O\|Y2KM7:TR?=	MWXTRW5ITVJ?
A704	MkHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fWfGlEPTB;MkOuOlExOyEQvF2=	MUXTRW5ITVJ?
LC-2-ad	NEfqOG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NITIbZNKSzVyPUKzMlYyPDdizszN	NX\QUo9RW0GQR1XS
VM-CUB-1	Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mo\VTWM2OD1{Mz63N\|QyKM7:TR?=	M{WyZXNCVkeHUh?=
PC-3	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{DzN2lEPTB;MkSuNFUzPiEQvF2=	M2\rU3NCVkeHUh?=
HEL	NUTLVmdsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGSw[3JKSzVyPUK0MlA5PjVizszN	MWrTRW5ITVJ?
ABC-1	M4TCNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVi5OYh3UUN3ME2yOE4zPzJ7IN88US=>	MWfTRW5ITVJ?
COLO-680N	MnO2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTwTWM2OD1{ND60O\|Y1KM7:TR?=	Ml22V2FPT0WU
MZ1-PC	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjWUVZKSzVyPUK0MlY5PyEQvF2=	NUfTTWdFW0GQR1XS
NCI-H69	M1jafGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\qTWM2OD1{ND63N\|U1KM7:TR?=	M2PUZ3NCVkeHUh?=
TE-1	M3frSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2C5S2lEPTB;MkWuNFQ6QSEQvF2=	MVnTRW5ITVJ?
EW-3	M17ZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn64TWM2OD1{NT6xNVMh\|ryP	Ml\pV2FPT0WU
PANC-08-13	M3HxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHHs[npKSzVyPUK1MlgyODNizszN	Ml3CV2FPT0WU
NMC-G1	NFfmSVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHLdpdKSzVyPUK2MlAxQDhizszN	NFzzOo9USU6JRWK=
BT-20	NWDaSJZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHvsTVhKSzVyPUK2MlQ2PDNizszN	MV\TRW5ITVJ?
TGBC24TKB	NGjyR\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4T0VmlEPTB;Mk[uO\|M{OSEQvF2=	MlLFV2FPT0WU
TE-11	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmW1TWM2OD1{Nj65PFk2KM7:TR?=	NYS1WnZGW0GQR1XS
ESS-1	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUnJR\|UxRTJ5LkOyNVYh\|ryP	NEfGWIpUSU6JRWK=
JVM-3	MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWfJR\|UxRTJ5Lk[0O\|Uh\|ryP	MV\TRW5ITVJ?
C3A	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHX1WVFKSzVyPUK3Mlg1QTZizszN	NXm1WmVHW0GQR1XS
MDA-MB-157	Mom4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXXuVXRoUUN3ME2yO{45PzV\|IN88US=>	NE[4ZmxUSU6JRWK=
KLE	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlv3TWM2OD1{OD6xNFU5KM7:TR?=	MYXTRW5ITVJ?
ES1	M4PUdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjYTWM2OD1{OD6xPFM5KM7:TR?=	MVHTRW5ITVJ?
CAL-120	MnntS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWXJR\|UxRTJ6LkO5PVkh\|ryP	MYfTRW5ITVJ?
NCI-N87	Mlu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTJ6LkWxNFUh\|ryP	MlzoV2FPT0WU
RPMI-8226	M1HmPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnTTTWM2OD1{OT6xPFQ{KM7:TR?=	Mo\XV2FPT0WU
COR-L88	M2m1fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoK2TWM2OD1{OT6yOFE6KM7:TR?=	NIPuTVNUSU6JRWK=
UACC-893	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUDJR\|UxRTJ7LkOxN\|ch\|ryP	MWjTRW5ITVJ?
C8166	NFjyepJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mo\pTWM2OD1{OT65PVk3KM7:TR?=	MVfTRW5ITVJ?
J82	MojNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWDWT29HUUN3ME2zNE45OTR5IN88US=>	MV7TRW5ITVJ?
PFSK-1	MlS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\xSGlEPTB;M{GuNFY2QSEQvF2=	NVrxSXkxW0GQR1XS
COLO-684	NWeyNmpXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmPsTWM2OD1\|MT60N\|c1KM7:TR?=	NX3mZ2d2W0GQR1XS
CAL-72	NYLpWXNsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVLJR\|UxRTNzLkW3Nlkh\|ryP	MmfuV2FPT0WU
SNB75	NULrZoNqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVHJR\|UxRTNzLki5O{DPxE1?	NVzzfmdGW0GQR1XS
MDA-MB-415	NHfhTFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH;GTndKSzVyPUOxMlk4PjJizszN	NFHVfFhUSU6JRWK=
SiHa	NXPBOFJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml3vTWM2OD1\|Mj60O\|EyKM7:TR?=	M3f4TnNCVkeHUh?=
NCI-H1648	M{fadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vTXmlEPTB;M{KuPVM1PSEQvF2=	MoLMV2FPT0WU
EFO-21	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVn5UJZCUUN3ME2zN{4xODVizszN	M3XUOXNCVkeHUh?=
HCC38	NVTHNnh1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEjh[lJKSzVyPUOzMlM5PDFizszN	MYrTRW5ITVJ?
IA-LM	NEG4PYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnHnTWM2OD1\|Mz63PFg6KM7:TR?=	MVfTRW5ITVJ?
CTV-1	M1vqW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEmxbnFKSzVyPUOzMlk4QDZizszN	NF:1SHJUSU6JRWK=
NCI-H446	NYnqe4FVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGnFbFZKSzVyPUO0MlI3QDlizszN	NE\JWGxUSU6JRWK=
IST-SL1	MkT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NH;VWmFKSzVyPUO0Mlc1ODhizszN	MmXyV2FPT0WU
EW-22	NWfzZlFTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NV\ZSY1pUUN3ME2zOE44PzV7IN88US=>	NWq1XGRzW0GQR1XS
JEG-3	NV;nZpM5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\qU4tNUUN3ME2zOk4yPzZ4IN88US=>	NHi1eZlUSU6JRWK=
LU-65	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVPJR\|UxRTN4LkK5PFUh\|ryP	M2HvUHNCVkeHUh?=
NCI-H596	NW\3NHBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHTMRo5KSzVyPUO2Mlk2QTFizszN	MXnTRW5ITVJ?
KNS-81-FD	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWDJR\|UxRTN5LkG0OUDPxE1?	M3;NR3NCVkeHUh?=
NCI-H1793	NIDzenRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTN5LkewPFYh\|ryP	NF;OZnFUSU6JRWK=
NCI-H460	MoHKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTN6LkC4O\|Mh\|ryP	MVrTRW5ITVJ?
MPP-89	M37xXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2X2TWlEPTB;M{muOVg5PiEQvF2=	MnS0V2FPT0WU
D-542MG	NFrpUXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV;JR\|UxRTN7Lki0N\|Yh\|ryP	NHHBV5hUSU6JRWK=
JAR	NUW0XGZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHicYZkUUN3ME20NE41PzB3IN88US=>	NGXtbllUSU6JRWK=
NCI-H209	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mli3TWM2OD12MD62O\|ch\|ryP	MYDTRW5ITVJ?
G-402	M2j3Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTRzLkO5PVMh\|ryP	NVrkW4dSW0GQR1XS
IST-MES1	NFfodmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTR{LkG5N\|Uh\|ryP	NVHseWF1W0GQR1XS
Daoy	NEPMeFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWrJR\|UxRTR{LkW0O\|Eh\|ryP	NXHkcmlsW0GQR1XS
EW-11	NXTrbW82T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYDJR\|UxRTR\|LkGyNVEh\|ryP	M2fFW3NCVkeHUh?=
Saos-2	M1PyRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTR\|LkG1N\|ch\|ryP	NY\5dHZPW0GQR1XS
no-10	NHjuUFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXLJR\|UxRTR\|LkG3NFIh\|ryP	MnTXV2FPT0WU
HCC1395	MkjKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnfWTWM2OD12Mz60OlQ1KM7:TR?=	NXHBR2dTW0GQR1XS
HCE-4	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LEcGlEPTB;NEOuO\|Y3PCEQvF2=	MWfTRW5ITVJ?
EW-1	M4PkUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnPyTWM2OD12Mz64NFQ6KM7:TR?=	Ml6yV2FPT0WU
OCUB-M	NGnkc4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml\ETWM2OD12ND6zOlM5KM7:TR?=	NH3DZpRUSU6JRWK=
IGR-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFu0WmRKSzVyPUS0MlQyOTVizszN	NEj1cnVUSU6JRWK=
NCI-H1838	NILkPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF71[XNKSzVyPUS0MlQ{PDlizszN	M1O4b3NCVkeHUh?=
NCI-H2405	NXLVUZVtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\YTWM2OD12ND61N\|Qh\|ryP	NUfBZYJpW0GQR1XS
GB-1	NWPxOVdjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\xdmlEPTB;NESuO\|Q3OyEQvF2=	MlmzV2FPT0WU
MG-63	NVjWeWtbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\UTWM2OD12Nj6wOlk3KM7:TR?=	MUfTRW5ITVJ?
KP-N-YN	NH\Nbm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEnPVHZKSzVyPUS2MlQ3PzlizszN	M4Owd3NCVkeHUh?=
no-11	MkHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmTBTWM2OD12Nz6wNlQ1KM7:TR?=	NWe1ZnB[W0GQR1XS
SW948	NFHRUoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTR5LkOzO\|ch\|ryP	NVHPfFg6W0GQR1XS
CAMA-1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLUc4piUUN3ME20O{4{PDN6IN88US=>	NF\vO3JUSU6JRWK=
HCC1187	NV\sU2VXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWnJR\|UxRTR5LkWxJO69VQ>?	NYXvOpM4W0GQR1XS
D-392MG	NFnScW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnS3TWM2OD12Nz62OVE3KM7:TR?=	MnXnV2FPT0WU
647-V	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoHOTWM2OD12OT6zOFE1KM7:TR?=	MnvWV2FPT0WU

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-ERK1/2 / ERK1/2 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK1/2 in sympathetic neurons. Immunoblots were performed with whole cell extracts from sympathetic neurons maintained in the presence of NGF and left untreated or treated with PD184352 at 0.1, 1, 2 or 10 μM for 16 hours. Antibodies to detect total ERK1/2 and phospho-ERK1/2 were used. p-ERK5 / ERK5 ; PubMed: 21762482 BMC Neurosci Effect of PD184352 on phosphorylation of ERK5 in sympathetic neurons.	21762482
Growth inhibition assay	Cell viability; PubMed: 29989268 Cancer Sci Relative viability of DU145CR cells treated with PD184352 was significantly less than that of DU145 cells in WST assay.	29989268

In vivo

Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. ^[1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. ^[2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. ^[5]

Protocol

Kinase Assay: ^[2]	- Collapse MEK1 Assay: MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of ³²P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl₂ /2 mM EGTA/10 μM [γ-³²P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research: ^[1]	- Collapse Cell lines: Colon 26 carcinoma cells Concentrations: 0.1-10 μM Incubation Time: 24 hours Method: Cells are planted seeded in T-75 cm ² flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry. (Only for Reference)
Animal Research: ^[3]	- Collapse Animal Models: PTC cells in athymic mice Dosages: 150 mg/kg Administration: Orally twice daily (Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	96 mg/mL (200.55 mM)
	Water	Insoluble
	Ethanol	'14 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 For best results, use promptly after mixing.	10 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download PD184352 (CI-1040) SDF

Molecular Weight	478.67
Formula	C₁₇H₁₄ClF₂IN₂O₂
CAS No.	212631-79-3
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	C1CC1CONC(=O)C2=C(C(=C(C=C2)F)F)NC3=C(C=C(C=C3)I)Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Selective MEK Inhibitor

Selumetinib (AZD6244) : MEK1-selective, IC50=14 nM.
Most Potent MEK Inhibitor

PD0325901 : MEK, IC50=0.33 nM,
FDA-approved MEK Inhibitor

Trametinib (GSK1120212) : Approved by FDA for BRAF V600E mutated metastatic melanoma.
Newest MEK Inhibitor

Binimetinib (MEK162, ARRY-162, ARRY-438162) : Potent inhibitor of MEK1/2 with IC50 of 12 nM.

Related MEK Products

Cobimetinib (GDC-0973) ^New

Cobimetinib (GDC-0973, RG7420) is a potent and highly selective MEK1 inhibitor with IC50 of 4.2 nM, showing more than 100-fold selectively for MEK1 over MEK2 and showed no significant inhibition when tested against a panel of more than 100 of serine-threonine and tyrosine kinases. Cobimetinib induces apoptosis. Phase 3.
BI-847325 ^New

BI-847325 is an orally bioavailable, and selective dual MEK/Aurora kinase inhibitor with IC50 of 3 nM, 25 nM, 15 nM, 25 nM, and 4 nM for Xenopus laevis Aurora B, human Aurora A and Aurora C, as well as human MEK1 and MEK2, respectively. Phase 1.
GDC-0623 ^New

GDC-0623 (G-868) is a potent and ATP-uncompetitive MEK1 inhibitor with K_i of 0.13 nM. Phase 1.
Trametinib (GSK1120212)

Trametinib (GSK1120212) is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assays, no inhibition of the kinase activities of c-Raf, B-Raf, ERK1/2. Trametinib activates autophagy and induces apoptosis.

Features:More potent than PD0325901 or AZD6244.
Mirdametinib (PD0325901)

Mirdametinib (PD0325901) is a selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM in cell-free assays, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2.
Selumetinib (AZD6244)

Selumetinib (AZD6244, ARRY-142886) is a potent, highly selective MEK inhibitor with IC50 of 14 nM for MEK1 and Kd value of 530 nM for MEK2. It also inhibits ERK1/2 phosphorylation with IC50 of 10 nM, no inhibition to p38α, MKK6, EGFR, ErbB2, ERK2, B-Raf, etc. Selumetinib suppresses cell proliferation, migration and trigger apoptosis. Phase 3.

Features:First MEK inhibitor being tested in Phase II clinical trials.
U0126-EtOH

U0126-EtOH is a highly selective inhibitor of MEK1/2 with IC50 of 0.07 μM/0.06 μM in cell-free assays, 100-fold higher affinity for ΔN3-S218E/S222D MEK than PD98059. U0126 inhibits autophagy and mitophagy with antiviral activity.

Features:A chemically synthesized and highly selective inhibitor of both MEK1 and MEK2.
PD98059

PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM in a cell-free assay, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. PD98059 is a ligand for the aryl hydrocarbon receptor (AHR) and functions as an AHR antagonist.

Features:Does not inhibit c-Raf phosphorylated MEK1.
Binimetinib (MEK162)

Binimetinib (MEK162, ARRY-162, ARRY-438162) is a potent inhibitor of MEK1/2 with IC50 of 12 nM in a cell-free assay. Binimetinib induces G1 cell cycle arrest and apoptosis in human NSCLC cell lines and induces autophagy. Phase 3.
Refametinib (RDEA119)

Refametinib (RDEA119, Bay 86-9766) is a potent, ATP non-competitive and highly selective inhibitor of MEK1 and MEK2 with IC50 of 19 nM and 47 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

PD184352 (CI-1040)